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Abstract
Background: Hypotension during anaesthesia for hip fracture surgery is common. Recent data suggest that there is an
association between the lowest intra-operative blood pressure and mortality, even when adjusted for co-morbidities.
This is consistent with data derived from the wider surgical population, where magnitude and duration of hypotension
are associated with mortality and peri-operative complications. However, there are no trial to data to support more
aggressive blood pressure control.
Methods/design: We are conducting a three-centre, randomised, double-blinded pilot study in three hospitals
in the United Kingdom. The sample size will be 75 patients (25 from each centre). Randomisation will be
done using computer-generated concealed tables. Both participants and investigators will be blinded to
group allocation. Participants will be aged >70 years, cognitively intact (Abbreviated Mental Test Score 7 or
greater), able to give informed consent and admitted directly through the emergency department with a
fractured neck of the femur requiring operative repair. Patients randomised to tight blood pressure control or
avoidance of intra-operative hypotension will receive active treatment as required to maintain both of the
following: systolic arterial blood pressure >80% of baseline pre-operative value and mean arterial pressure >75 mmHg
throughout. All participants will receive standard hospital care, including spinal or general anaesthesia, at the discretion
of the clinical team. The primary outcome is a composite of the presence or absence of defined cardiovascular, renal
and delirium morbidity within 7 days of surgery (myocardial injury, stroke, acute kidney injury, delirium). Secondary
endpoints will include the defined individual morbidities, mortality, early mobility and discharge to usual residence.
Discussion: This is a small-scale pilot study investigating the feasibility of a trial of tight intra-operative blood pressure
control in a frail elderly patient group with known high morbidity and mortality. Positive findings will provide the basis
for a larger-scale study.
Trial registration: ISRCTN Registry identifier: ISRCTN89812075. Registered on 30 August 2016.
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Background
Recently, observational data derived from 11,000
patients in the Anaesthesia Sprint Audit of Practice
(ASAP) study [1, 2] have shown that regardless of anaes-
thetic technique or definition, hypotension during hip
fracture surgery is very prevalent. Seventy-eight percent
and 62% of patients receiving general and spinal anaes-
thesia, respectively, had a 30% or greater decrease in sys-
tolic blood pressure, whilst 40% and 22%, respectively,
had mean arterial pressure (MAP) <55 mmHg. In a
general surgical population, this MAP threshold is
associated with significantly higher 30-day post-operative
mortality and prolonged length of inpatient stay [3]. ASAP
data support this observation [2]: 30-day post-operative
mortality was significantly higher among patients whose
MAP fell below 55 mmHg intra-operatively than among
those whose lowest MAP remained above this threshold
(6.0% vs 4.6%, p = 0.002).
However, it has been argued that 30-day mortality is
an insensitive proxy outcome measure of anaesthetic
intervention in hip fracture management. It occurs
30 days after the intervention and so will be affected by
any number of other factors that are unrelated to an-
aesthesia [4]. Other recent large U.S. retrospective ob-
servational studies of general surgical patients have
found significant associations between intra-operative
hypotension (MAP <55 mmHg) and increased risk of
cerebrovascular accident [5], acute kidney injury and
myocardial injury [6, 7], suggesting a plausible causa-
tive link between anaesthesia-induced hypotension
and early post-operative ‘ischaemic’ complications.
Prospectively, strict blood pressure control as part of
protocolised treatment aimed at maintaining cerebral
oxygenation has been found to significantly reduce
the incidence of mild and moderate post-operative
cognitive dysfunction [8–10]. Myocardial injury and
acute kidney injury [11, 12] after hip fracture are in-
dependently associated with poorer outcomes (in-
creased mortality and institutionalisation, prolonged
length of stay and return to mobility) among patients
with hip fracture.
On the basis of this body of research, we hypothe-
sise that intra-operative hypotension causes critical
ischaemia/hypoperfusion of the brain, heart and kid-
neys in older, frailer patients with hip fracture who
have co-morbidities, producing measurable post-
operative alterations in organ function and resulting
in poorer outcome, We propose a prospective, multi-
centre, randomised controlled trial comparing proto-
colised intra-operative control of blood pressure with
standard treatment, using a composite of defined car-
diovascular, renal and delirium outcomes within 7 days
as the primary outcome and 30-day post-operative
mortality, fitness for hospital discharge, return to baseline
mobility level and return to independent living as second-
ary outcomes. This paper describes the protocol for an in-
ternal pilot feasibility study prior to the main trial.
Methods/design
The trial protocol has been prepared and is reported in ac-
cordance with the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidance
[13, 14] (see Additional file 1: Figure S1, Additional file 2).
Study objectives
Primary aims
We aim to complete an internal pilot feasibility study to
test the hypothesis that tighter intra-operative control of
blood pressure improves a composite outcome of pres-
ence or absence of defined cardiovascular, renal and de-
lirium morbidity within 7 days of hip fracture surgery
compared with standard treatment.
Secondary aims
Secondary aims are to discover whether tighter intra-
operative control of blood pressure has beneficial effects
on other measures of patient outcome and to provide
data to support a full trial, including estimates of pri-
mary and secondary outcome rates/distribution, separ-
ation of blood pressure control between groups, and
recruitment rates.
Study design
This is a prospective, parallel-group, double-blind (par-
ticipant and investigator), randomised controlled clinical
trial. Three centres will participate. Recruitment com-
menced on 22 December 2016, and total recruitment is
expected to take 12 months.
Study setting
The study setting comprises three U.K. secondary hospi-
tals providing acute care for patients with hip fracture.
Each hospital admits over 400 patients with hip fracture
each year.
Randomisation and blinding
Randomisation (on a one-to-one basis) will be carried
out via security-sealed, sequentially numbered opaque
envelopes containing details of group allocation. The se-
quence generation and preparation of envelopes are
done by an individual not involved in the trial. Random-
isation is computer-generated in blocks of unequal size
using a random seed known only to this individual. Ran-
domisation is stratified by intended mode of anaesthesia
(spinal vs general anaesthesia) and Nottingham Hip
Fracture Score (NHFS) (≤4 vs ≥5) [15]. The sequence is
not revealed until data are locked. Participants will be
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randomised in the anaesthesia room immediately prior
to induction of anaesthesia by the attending anaesthetist.
The investigators, patients, nurses and data-collecting
staff will all be blinded to treatment allocation. The at-
tending anaesthetist will not be blinded to treatment
allocation.
Assessment of mobility will be made by the ward phys-
iotherapists treating the patient. Patients are declared
medically fit for discharge by the multi-professional team
when all are satisfied that the participant has no ongoing
needs for acute hospital care. This team is blinded to par-
ticipant allocation.
Selection of participants
Recruitment
Participants will be identified by emergency department
staff, trauma co-ordinator nurses and the orthopaedic
and anaesthesia clinical teams, which will then inform a
member of the research team about the presence of the
patient. Once the patient is identified, a member of the
research team will approach the patient, conduct initial
screening and take consent from of the patient. Active
participation in the study will be until the 30-day follow-
up phone call.
Participants will be informed that participation is vol-
untary and that they are free to withdraw at any time
without affecting their care. Data on time to discharge
and mortality are routinely collected for all patients with
hip fracture at each institution, and participation in the
trial will involve consent for this data to be used. Pa-
tients unable to provide informed consent will be ex-
cluded from the trial. Patients for whom language will
be a barrier will also be excluded, owing to the small-
scale nature of the study; patient information will not be
available in languages other than English. In practice,
non-English speakers represent a very small number of
patients in this population group.
Inclusion criteria
 Primary hip fracture listed for surgical repair
 Aged >70 years
 Able to give informed consent
Exclusion criteria
 Any condition or impairment which, in the view of
the investigator, would prohibit the patient from full
participation in the study
Standard care
Standard care will be identical in both groups. Only the
control of intra-operative blood pressure will be different.
All patients are admitted to dedicated trauma wards
and cared for in units that have written processes for ad-
ministration of pre-operative fluids, choice of ortho-
paedic repair, and early mobilisation. All three units
have policies mapped to national U.K. standards
(National Institute for Health and Care Excellence
[16], British Orthopaedic Association Standards for
Trauma [17], Association of Anaesthetists of Great
Britain and Ireland [18, 19] and Best Practice Tariff
[20]).
This includes assessment by orthogeriatricians, op-
eration within 36 hours of admission and assessment
of bone health and falls. All patients are cared for
under a hip fracture care pathway, which involves
rapid assessment and admission from the emergency
department, intravenous crystalloid infusions from the
time of admission, and multi-professional care and
discharge planning. Operations are performed in dedi-
cated trauma theatres by appropriately experienced
surgeons and anaesthetists.
In both groups, the attending anaesthetist will be re-
sponsible for provision of adequate analgesia and anaes-
thesia and appropriate post-operative fluid, haemoglobin
and pain management. At a minimum, the following will
be done:
 Haemoglobin concentrations will be maintained
>80 g/L in both groups.
 Haemoglobin will be measured in the post-
anaesthesia care unit using a point-of-care haemo-
globin analyser (HemoCue™; Fisher Scientific, Pitts-
burgh, PA, USA) in all patients.
 Blood transfusion will be started in recovery if
deemed clinically necessary.
 All patients will be encouraged to eat and drink as
soon as possible following surgery.
 Regular paracetamol will be prescribed (dose
adjusted if necessary).
 Rescue analgesia will be prescribed, avoiding non-
steroidal anti-inflammatory drugs.
Surgical technique will be in line with standard na-
tional policies, though individual patient circumstances
may require deviation from these on occasion, as follows:
 Displaced intra-capsular fracture: cemented
hemiarthroplasty
 Extracapsular fracture: dynamic hip screw
 Sub-trochanteric fracture: dynamic hip screw or
femoral nail
Concomitant medication
Analgesia will be provided in accordance with normal
practice at the study centre. Non-steroidal anti-
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inflammatory drugs are not routinely prescribed for this
group of patients, owing to side effects. Other medica-
tions will be prescribed by the attending medical staff as
appropriate for each individual. Thromboprophylaxis
with subcutaneous low-molecular-weight heparin is
routine.
Concomitant treatments
Anaesthesia will be at the discretion of the attending an-
aesthetist; both spinal and general anaesthesia may be
used. Peri-operative use of nerve blocks (femoral or
fascia iliaca) is encouraged but not mandated in all of
the units. Other post-operative therapies, such as
physiotherapy, will be applied in accordance with rou-
tine hospital practice at the relevant centre.
Study intervention
Patients randomised to standard blood pressure control
will receive routine care. Fluids and vasopressor drugs
will be used as deemed clinically appropriate by the at-
tending anaesthetist.
Patients randomised to tight blood pressure control or
avoidance of intra-operative hypotension will receive
active treatment as required to maintain both of the
following:
 Systolic arterial pressure >80% of baseline pre-
operative value
 MAP >75 mmHg throughout
These targets have been purposefully set relatively high
because we anticipate that, although there may be failure
to achieve this target in all patients, intervention groups
will be less likely to fall below thresholds with stronger
associations with a poor outcome. The order and doses
of treatments to achieve this will depend upon the clin-
ical scenario but will include the following:
 Fluid bolus to ensure adequate intra-vascular volume
(associated with reduced requirement for vasoactive
drugs [11])
 Combined β-/α-1-adrenergic agonist (ephedrine)
 More selective α-1-adrenergic agonist (metaraminol)
Baseline pre-operative blood pressure will be defined
as the mean of two readings taken at least 5 minutes
apart after the patient has arrived in the induction room
for anaesthesia. Patients will receive any anaesthetic
technique deemed suitable by the attending anaesthetist
in consultation with the patient and/or the patient’s rela-
tives. Blood pressure will be measured using standard
non-invasive equipment every 2.5 minutes or continuous
non-invasive blood pressure monitoring in the interven-
tion group. The frequency of blood pressure monitoring
will be at the attending anaesthetist’s discretion in the
control group, but at least every 5 minutes.
In addition to their normal care, each participant will
be screened daily for the following:
 Delirium using the 4 A’s Test (rapid assessment test
for delirium) (4AT) tool: The 4AT is a four-question
screening tool for delirium that will be performed by
either the ward nursing staff or a member of the re-
search team.
 Blood tests for renal function (including estimation of
glomerular filtration rate) and troponin I: These
blood tests will be ordered with routine clinical care
tests to reduce any additional burden for
participants. Blood tests are typically ordered on 3
or 4 of the first 7 post-operative days.
A telephone follow-up call will be made to the patient
(or their carer/close family member, or general practi-
tioner [primary care physician] with appropriate con-
sent) at 30 days to determine place of residence and
functional status. Mortality status will be determined
from administrative records at 1 year.
Patient and process characteristics
Data will be recorded for pre-operative and intra-
operative characteristics listed below.
Pre-operative
 Usual place of residence
 Date/time of admission
 Mobility prior to fracture
 Medical co-morbidities
 Frailty score [21]: 35-point version of Searle frailty
index (excluding variables likely to be undefinable in
patients with hip fracture)
 NHFS [15, 22–24]
 Full blood count
 Urea and electrolytes
 Arterial blood pressure (systolic, mean and diastolic)
– Last ward measurement
– Mean of two measurements 5 minutes apart in
anaesthesia room before induction of anaesthesia
Intra-operative
 Timing/duration of surgery and anaesthesia
 Mode of anaesthesia and analgesia
Outcome measures
Complications will be categorised according to European
Perioperative Clinical Outcome (EPCO) definitions [25]
as follows:
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 Incidence of acute kidney injury in the first 7 days,
defined as follows:
– Stage 1: An increase in serum creatinine (sCr) of
1.5 to 1.99 times baseline or ≥0.3 mg/dl
(≥26.5 μmol/L) increase
– Stage 2: An increase in sCr of between 2 to 2.99
times baseline
– Stage 3: An increase of three times or
more baseline or increase in sCr to
≥4.0 mg/dl (≥353.6 μmol/L) after previous
stage 1 or initiation of renal replacement
therapy (a retrospective staging)
 Incidence of delirium in the first 7 days,
defined using the AT4 [26, 27] delirium
screening tool (This is a deliberate difference
from EPCO due to specific evidence base for
AT4 in hip fracture.)
 Incidence of myocardial injury after
non-cardiac surgery in the first 3 days,
defined as troponin >0.03 ng/ml judged to
be due to myocardial injury in the absence
of other causes
 Stroke: Embolic, thrombotic or haemorrhagic
cerebral event with persistent residual motor,
sensory or cognitive dysfunction [28]
 Length of hospital stay
 In-hospital mortality, 5- and 30-day mortality
 Quality of life recorded by EQ-5D [29] at 30 days
 1-year mortality
 Ability to mobilise on 4-point scale compared with
pre-morbid mobility
The ability of intervention group participants to achieve
blood pressure limits will be assessed using a variety of
methods:
 Nadir blood pressure (single lowest post-induction
blood pressure)
 Absolute time below blood pressure limits
 Proportion of intra-operative time below blood pres-
sure limits
Statistical considerations
The primary outcome is a composite of presence or ab-
sence of defined cardiovascular, renal and delirium mor-
bidity within 7 days of surgery:
 Myocardial injury following non-cardiac surgery or
 Stroke or
 Acute kidney injury or
 Delirium
Secondary outcomes are as follows:
 Presence or absence of each of the defined
cardiovascular, renal and delirium morbidity within
7 days of surgery
 5-day post-operative mortality
 30-day post-operative mortality
 Operation to fit-for-discharge time
 Operation to up-and-walk time
 Proportion returning to pre-operative place of
residence
 Prevalence of bone cement implantation syndrome
[30]
The primary outcome is a composite binary outcome
and will be analysed using chi-square statistics. Most of
the supportive secondary outcomes are also binary out-
comes and will be analysed similarly. Time data (e.g.,
length of stay) will be tested for normality. It is expected
that reciprocal or logarithmic transformation will be re-
quired. Appropriate independent group tests (Student’s t
or Mann-Whitney U test will be used). Mortality data
will be analysed both as a binary outcome (30-day mor-
tality, chi-square test) and using survival analysis (Cox
regression). No formal interim analyses are planned.
Sample size and justification
The incidence of acute kidney injury in patients with hip
fracture is reportedly between 24% [12] and 45% [11].
Myocardial injury evidenced by elevated troponin occurs
in about 27% of patients with hip fracture [31]. Delirium
is variously reported. In our preliminary data (local pilot
of 4AT tool), we found 20% patients had delirium. In a
recent prospective study done in the United States in
which researchers used the Confusion Assessment
Method, an incidence of 33% of delirium was reported
on post-operative day 2 [32]. In the recently reported
neck of femur optimisation therapy - targeted stroke vol-
ume study (NOTTS) [11], which had a less robust col-
lection of delirium data, researchers found that 56% of
patients overall developed a cardiac, renal or neuro-
logical complication: 63% in the control group and 47%
in the intervention group. A pessimistic assumption of a
reduction in composite event rate from 50% to 45%
would require a definitive trial size of around 4500 pa-
tients, accounting for a 10% drop-out rate.
Existing studies indicate an incidence of major organ
dysfunction and major complications post-operatively in
this population on the order of 20%. If tight blood pres-
sure control peri-operatively decreased this incidence to
15% (a 25% improvement; similar to the effect size seen
in NOTTS [11]), then 1250 patients would need to be
randomised to each group to demonstrate this difference
if the type I error rate were 5% and the type II error rate
were 10% (power of 90%).
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Discussion
We are conducting a small-scale pilot feasibility study.
Although there is mounting evidence of the association
between intra-operative hypotension and worse out-
come, there are few data demonstrating a causal link or
that intervention is beneficial. Recent studies of cardiac
output-guided fluid therapy in patients with hip fracture
have provided inconclusive results [11, 33].
We have deliberately chosen a pragmatic intervention to
manage intra-operative blood pressure. Hypotension dur-
ing surgery and anaesthesia is multi-factorial, with a com-
bination of previous and ongoing blood loss, dehydration,
vasodilation (venous and arterial) and myocardial depres-
sion resulting from general or spinal anaesthesia, and con-
comitant drug therapy. The choice of fluids and vasoactive
drugs for use in management is therefore dependent on
the patient, the attending anaesthetist and the dynamic
clinical situation. We therefore feel it is inappropriate, and
also impractical, to protocolise how blood pressure is man-
aged during anaesthesia.
The patients at greatest risk of complications following
hip fracture are the frailer patients. Because this is a
pilot study, patients who lack capacity are not being in-
cluded. This therefore excludes the group that may have
most to gain from the intervention [34]. We hope to ad-
dress this in the main trial. As part of the pilot, we will
be assessing the acceptability of the study to patients
and their relatives. This information will inform the full
trial design.
The study is unavoidably not blinded for the attending
anaesthetist, and there is of course a risk that practice
will drift towards the intervention practice. However, the
high rates of hypotension observed during the ASAP
study suggest that widespread ‘normal’ practice is not
currently particularly effective at preventing hypotension.
Intra-operative blood pressures are being recorded to as-
sess the separation between groups.
There are myriad definitions of intra-operative
hypotension. For this pilot study, we have chosen plaus-
ible, and we believe achievable, targets. Prior to a full
study, these targets will be reassessed in light of infor-
mation gained from the pilot study. Similarly, there is no
single agreed definition of ‘normal’ blood pressure, par-
ticularly in the emergency patient, who may be affected
by pain, anxiety, dehydration and hypovolaemia. The
protocol explicitly allows for the attending anaesthetist
to over-ride the anaesthesia room blood pressures
(before the intervention starts) if these are felt to be
non-representative.
We have chosen to limit the duration of the interven-
tion to solely during anaesthesia, and not in the recovery
or ward phases. Although hypotension in the recovery/
post-anaesthesia care unit and the ward are anecdotally
relatively common we felt it inappropriate to extend the
intervention. This was for two reasons. First, in practical
terms, during the period of anaesthesia and surgery, pa-
tients receive one-to-one care from a physician with the
skills and resources to promptly and effectively prevent
and treat cardiovascular disturbances. This is not the
case in the ward, so an extended intervention period
would not be practical outside a trial environment. Sec-
ond, if the intervention is effective, then we anticipate
that some of the causes of post-operative hypotension
will have been mitigated before the post-operative
period.
The anaesthetic and surgical episode is only a rela-
tively brief period in the longer course of post-injury re-
habilitation. Although it is possible that intra-operative
management has no effect on longer-term outcome, the
data derived from the ASAP study and other studies of
intra-operative hypotension support the premise that it
may have effects well beyond the immediate post-
operative period. Improvements in hip fracture outcome
have been associated with greater standardisation of sur-
gical care and orthogeriatric care. Anaesthesia currently
has relatively limited evidence on which to base stan-
dards [35]. The results of this study and the main trial
would be expected to provide this evidence.
We have chosen a composite of four plausible, medic-
ally important complications. There is no good mechan-
istic reason to choose any one ahead of the others, and
we therefore feel this is an appropriate approach. We
hope that if this study shows positive effects, it will serve
as a guide for larger studies investigating blood pressure
control in both patients with hip fracture and more
widely in older patients.
Trial status
As of 14 July 2017, 22 of the planned 75 participants
had been randomised.
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